This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smits, R.C.F. Articles by Polman, C. H. Search for Related Content PubMed PubMed Citation Articles by Smits, R.C.F. Articles by Polman, C. H.

NEUROLOGY 1994;44:1701
© 1994 American Academy of Neurology

The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis

A pilot study R.C.F. Smits, MD, H. H. Emmen, MSc, F. W. Bertelsmann, MD, PhD, B. M. Kulig, PhD, A. C. van Loenen, PharmD and C. H. Polman, MD, PhD

Departments of Neurology (Drs. Smits, Bertelsmann, and Polman) and Pharmacy (Dr. van Loenen), Free University Hospital, Amsterdam; and the Department of Neurotoxicology and Reproduction Toxicology (Dr. Kulig and H.H. Emmen), TNO Nutrition and Food Research Institute, Rijswijk, The Netherlands.

4 Aminopyridine (4-AP) has a favorable effect on the disability of certain patients with MS. We investigated the effect of 4-AP on neuropsychological performance in 20 MS patients using a randomized, double-blind, placebo-controlled, crossover design. Although there was a trend for improved performance with 4-AP for two of the tests, we could not demonstrate significant effects of 4-AP on cognitive function.

Address correspondence and reprint requests to Dr. Chris H. Polman, Department of Neurology, Free University Hospital, P.O. Box 7057,1007 MB Amsterdam, The Netherlands.

Supported by the Foundation for the Support of MS Research, The Hague, The Netherlands.

Received December 7, 1993. Accepted in final form March 15, 1994.

This article has been cited by other articles:

				M P Amato, E Portaccio, B Goretti, V Zipoli, L Ricchiuti, M F De Caro, F Patti, R Vecchio, S Sorbi, and M Trojano The Rao's Brief Repeatable Battery and Stroop test: normative values with age, education and gender corrections in an Italian population Multiple Sclerosis, November 1, 2006; 12(6): 787 - 793. [Abstract] [PDF]

				L. B. Krupp, C. Christodoulou, P. Melville, W. F. Scherl, W. S. MacAllister, and L. E. Elkins Donepezil improved memory in multiple sclerosis in a randomized clinical trial Neurology, November 9, 2004; 63(9): 1579 - 1585. [Abstract] [Full Text] [PDF]

				E. A. DeSousa, R. H. Albert, and B. Kalman Cognitive impairments in multiple sclerosis: A review American Journal of Alzheimer's Disease and Other Dementias, January 1, 2002; 17(1): 23 - 29. [Abstract] [PDF]

				J B Boringa, R H. Lazeron, I E. Reuling, H J Ader, L E. Pfennings, J Lindeboom, L M. de Sonneville, N F Kalkers, and C H Polman The Brief Repeatable Battery of Neuropsychological Tests: normative values allow application in multiple sclerosis clinical practice Multiple Sclerosis, August 1, 2001; 7(4): 263 - 267. [Abstract] [PDF]

				A. Weinstein, S. I. L. Schwid, R. B. Schiffer, M. P. McDermott, D. W. Giang, and A. D. Goodman Neuropsychologic Status in Multiple Sclerosis After Treatment With Glatiramer Arch Neurol, March 1, 1999; 56(3): 319 - 324. [Abstract] [Full Text] [PDF]

				A M Plohmann, L Kappos, W Ammann, A Thordai, A Wittwer, S Huber, Y Bellaiche, and J Lechner-Scott Computer assisted retraining of attentional impairments in patients with multiple sclerosis J. Neurol. Neurosurg. Psychiatry, April 1, 1998; 64(4): 455 - 462. [Abstract] [Full Text] [PDF]